PROCEPT BioRobotics (PRCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting will be held virtually on June 9, 2026, with shareholders voting on director elections, auditor ratification, and executive compensation approval.
Only shareholders of record as of April 10, 2026, are eligible to vote, with detailed instructions for both record and beneficial holders.
The company emphasizes virtual meetings for broader access, cost savings, and environmental benefits.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class II directors (Antal Desai, Mary Garrett, Frederic Moll, M.D.) for terms expiring in 2029.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026 is on the agenda.
A non-binding advisory vote on executive compensation (say-on-pay) is included.
Board recommends voting FOR all proposals.
Procedures for submitting shareholder proposals and nominations for the 2027 meeting are detailed, with deadlines and requirements.
Board of directors and corporate governance
The board consists of nine members divided into three staggered classes, with a majority deemed independent under Nasdaq standards.
Chair and CEO roles are separated to reinforce board independence.
Board committees include Audit, Compensation, and Nominating & ESG, all composed of independent directors.
Directors are encouraged to attend annual meetings; board and committee attendance exceeded 75% in 2025.
Stock ownership policy requires directors to hold shares valued at five times their base annual retainer.
Latest events from PROCEPT BioRobotics
- Q2 revenue up 61% year-over-year, gross margin at 59%, and cash reserves strong at $214.1M.PRCT
Q2 20248 Jul 2026 - Aquablation's clinical success and broad coverage drive rapid adoption and expansion in urology.PRCT
45th Annual William Blair Growth Stock Conference8 Jul 2026 - Q3 2024 revenue up 66% with record gross margin and HYDROS launch driving strong growth.PRCT
Q3 20248 Jul 2026 - Aquablation is poised for leadership in BPH and prostate cancer, with accelerating growth and margin expansion.PRCT
Conference presentation2 Jul 2026 - Operational realignment and clinical innovation drive growth and profitability in BPH and prostate cancer.PRCT
46th Annual William Blair Growth Stock Conference2 Jun 2026 - Revenue, margin, and growth initiatives exceeded targets; new strategies and trials drive future upside.PRCT
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue up 20% to $83.1M, gross margin 65%, net loss widens, guidance strong.PRCT
Q1 20261 May 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay on June 9, 2026.PRCT
Proxy filing23 Apr 2026 - Launch teams, inventory optimization, and HYDROS upgrades set the stage for growth in 2024–2026.PRCT
TD Cowen 46th Annual Health Care Conference2 Mar 2026